Table 4.
Patients characteristics survival.
| Survivors | Range | Non-survivors | Range | p | |
|---|---|---|---|---|---|
| n | 90 | 94 | |||
| Male | 60 (66.7%) | 74 (78.7%) | |||
| Age [years] | 64 (58;70) | 25–83 | 68 (63; 75) | 33–92 | < 0.05 |
| Body-Mass-Index [kg/m2] | 30.45 (26.12; 34.26) | 20.81–52.47 | 27.78 (25.48; 33.14) | 18.94–70.31 | |
| Time from first symptom to hospital admission [days] | 5 (0; 7) | 0–50 | 4.5 (0; 8) | 0–23 | |
| Time from first symptom to admission to our ICU [days] | 10 (5; 14) | 0–28 | 11 (5; 16) | 0–35 | |
| Time from first symptom to ECMO therapy [days] | 16 (13; 22) | 4–25 | 15 (11; 23) | 0–31 | |
| Direct transfer to our ICU from other hospital | 55 (61.1%) | 66 (70.2%) | |||
| External tracheostomy | 6 (6.7%) | 8 (8.5%) | |||
| External intubation | 60 (66.7%) | 73 (77.7%) | |||
| Invasive mechanical ventilation before admission to our ICU [days] | 2 (0; 5) | 0–20 | 3 (0; 7) | 0–16 | |
| Non-invasive mechanical ventilation before admission to our ICU [days] | 2 (1; 3) | 1–18 | 2 (1; 4) | 1–22 | |
| Charlson ComorbidityIndex | 3 (2; 5) | 0–11 | 3 (2; 6) | 0–12 | |
| Arterial Hypertension | 66 (73.3%) | 65 (69.1%) | |||
| Cardiovascular disease | 21 (23.3%) | 24 (25.5%) | |||
| Neurovascular symptoms | 9 (10%) | 9 (9.6%) | |||
| Coronary artery disease | 15 (16.7%) | 16 (17.0%) | |||
| Thromboembolic events in medical history | 4 (4.4%) | 7 (7.4%) | |||
| Chronic arrhythmias | 14 (15.6%) | 23 (24.5%) | |||
| COPD | 8 (8.9%) | 5 (5.3%) | |||
| Other pulmonary disease | 3 (3.3%) | 8 (8.5%) | |||
| Nicotine abuse | 8 (8.9%) | 4 (4.3%) | |||
| Diabetes mellitus | 42 (46.7%) | 37 (39.4%) | |||
| Previous organ or bone marrow transplantation | 4 (4.4%) | 5 (5.3%) | |||
| Chronic renal failure | 12 (13.3%) | 16 (17.0%) | |||
| Chronic need of renal replacement therapy | 1 (1.1%) | 7 (7.4%) | |||
| Admission with trauma | 6 (6.7%) | 2 (2.1%) | |||
| ACE inhibitors | 26 (28.9%) | 17 (18.3%) | |||
| AT2 receptor blocker | 23 (25.6%) | 29 (31.2%) | |||
| Beta blocker | 36 (40.0%) | 38 (40.9%) | |||
| Antithrombotic drug | 24 (26.7%) | 25 (26.9%) | |||
| DOAC | 13 (14.4%) | 17 (18.3%) | |||
| Corticosteroids | 11 (12.2%) | 10 (10.8%) | |||
| Immunosuppressive Drugs | 4 (4.4%) | 6 (6.5%) | |||
| Nosocomial infection | 8 (8.9%) | 11 (11.7%) |
Data are median (Interquartile range) or n (%).
Significant values are in [bold].
ICU Intensive care unit, ECMO extracorporeal membrane oxygenation, NIV Non-invasive ventilation, COPD Chronic obstructive pulmonary disease, ACE Angiotensin-converting enzyme, AT2 Angiotensin II, DOAC Direct oral anticoagulants.